Research > Focus A
Dr. med. Erik Jung
University Hospital Heidelberg, Neurology Clinic
Within the frame of Focus A, patient groups likely to benefit from an alkylating or molecularly targeted intervention will be characterized. In addition, predictive biomarkers will be selected and prioritized, and parallel as well as subsequent treatments will be developed to enhance therapeutic benefit in selected molecularly defined subgroups. Overarching goals of the work packages in Focus A are the discovery of molecular lesions relevant for resistance to alkylating chemotherapy (A04, A05, A06), to treatments other than alkylating agents in glioblastoma and a priori unlikely to respond to alkylating treatment (A02, A03) and the unbiased screening for targets against the network structure (A01).
Link to: A01: Targeting tumor cell networks to overcome primary and adaptive resistance in glioblastoma
A01
TARGETING TUMOR CELL NETWORKS TO OVERCOME PRIMARY AND ADAPTIVE RESISTANCE IN GLIOBLASTOMA
Prof. Dr. med. Frank Winkler
University Hospital Heidelberg, Neurology Clinic
Link to: A02: Development of a specific combination therapy for histone H3-mutant pediatric glioblastoma
A02
DevelopMENT of a specific combination therapy for Histone H3-Mutant pediatric glioblastoma
David T. W. Jones, PhD
Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Paediatric Glioma Research Group
Prof. Dr. med. Olaf Witt
Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), University Hospital Heidelberg, Department of Pediatric Oncology and Hematology
Link to: A03: Deciphering resistance against targeted treatments
A03
Deciphering resistance against targeted treatments
Dr. med. Tobias Kessler
University Hospital Heidelberg, Department of Neurology/Neurooncology
Prof. Dr. med. Wolfgang Wick
University Hospital Heidelberg, Department of Neurology/Neurooncology,
Link to: A04: Evolution of IDH mutant gliomas during malignant progression
A04
Evolution of IDH mutant gliomas during malignant progression
Sevin Turcan, PhD
University Hospital Heidelberg, Department of Neurology
Link to: A05: Predictive biomarkers for MGMT-promoter-methylated glioblastoma
A05
Predictive biomarkers for MGMT-promoter-methylated glioblastoma
Prof. Dr. med. Andreas von Deimling
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology
PD Dr. med. David E. Reuss
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology
Link to: A06: Resistance mechanisms of glioblastoma against alkylating agents and radiotherapy
A06
Resistance Mechanisms of glioblastoma against alkylating agents and radiotherapy
Dr. biol. hum. Violaine Goidts
German Cancer Research Center (DKFZ), Junior Research Group Brain Tumor Therapeutic Targets
PD Dr. med. Felix Sahm
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology